Internal Medicine
M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.
18 May, 2021 | 07:50h | UTC
Analysis: Where are we with drug treatments for covid-19?
18 May, 2021 | 07:47h | UTCWhere are we with drug treatments for covid-19? – The BMJ
#ACC21 – The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030 – “The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women”.
18 May, 2021 | 07:32h | UTCHomepage: The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030 – The Lancet (free registration required)
Infographic: Women and cardiovascular disease
Video: The Lancet women and cardiovascular disease Commission
News release: Experts call for urgent action to reduce global burden of cardiovascular disease in women by 2030 – The Lancet
Commentary on Twitter (thread – click for more)
Cardiovascular disease is responsible for 35% of deaths in women yearly—yet remains:
❣️Understudied
❣️Under-recognised
❣️Underdiagnosed
❣️UndertreatedNEW @TheLancet Commission outlines 10 recommendations to improve health outcomes for millions of women: https://t.co/DDB97FFunC pic.twitter.com/WjV3aqqLV9
— The Lancet (@TheLancet) May 17, 2021
#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.
18 May, 2021 | 07:34h | UTCAspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial – The Lancet (free registration required)
Commentaries: Harmonizing Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy – HOST-EXAM – American College of Cardiology AND Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM – TCTMD
Commentary on Twitter
The sensational news of the day comes from South Korea. In a timely comparison of single antiplatelet monotherapies, clopidogrel beats aspirin during the chronic maintenance period after PCI, with curves diverging at 9 months. #ACC21https://t.co/Pp49LxcNWf pic.twitter.com/J9Un4QHzgL
— Davide Capodanno (@DFCapodanno) May 16, 2021
WHO study estimates long working hours causing 745.000 deaths a year from heart disease and stroke.
18 May, 2021 | 07:29h | UTCNews Release: Long working hours increasing deaths from heart disease and stroke: WHO, ILO – World Health Organization
Commentary: Long working hours killing 745,000 people a year, study finds – BBC
Commentary on Twitter (thread – click for more)
🆕 WHO & @ilo analysis shows that working 55 hours or more per week impacts #WorkersHealth & increases risk of cardiovascular diseases.
Long working hours led to 745 000 deaths from #stroke & ischemic heart disease in 2016, a 2⃣9⃣% rise ↗️ since 2000.
👉 https://t.co/T3nuPX3nH7 pic.twitter.com/UW5XxbjWqo
— World Health Organization (WHO) (@WHO) May 17, 2021
M-A: Screening test (Hospital Anxiety and Depression Scale – HADS-D) can identify hospitalized patients with depression.
18 May, 2021 | 07:23h | UTCKnowledge translation tool: Using the HADS-D to Screen for Depression
Commentary on Twitter (thread – click for more)
Our @DepressdP IPDMA on HADS-D accuracy, led by Dr. Yin Wu, was published today in @bmj_latest! We pooled data from 101 studies and found that a cutoff of >=7 maximized combined sensitivity and specificity. Read more here: https://t.co/iMmsjoeW7f
— Brooke Levis (@blevis_epi) May 10, 2021
Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.
18 May, 2021 | 07:27h | UTC
Expert consensus on peri-operative myocardial injury screening in noncardiac surgery.
18 May, 2021 | 07:12h | UTCInvited Commentary: Expert consensus on peri-operative myocardial injury screening in noncardiac surgery
NICE Guideline Update | Headaches in over 12s: diagnosis and management.
18 May, 2021 | 07:14h | UTCHeadaches in over 12s: diagnosis and management – National Institute for Health and Care Excellence
WSES-AAST guidelines: Management of inflammatory bowel disease in the emergency setting.
18 May, 2021 | 07:15h | UTC
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
17 May, 2021 | 08:49h | UTC
Commentaries on Twitter
DARE-19 trial #ACC21 @ACCinTouch
Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile
🎯 Do not discontinue SGLT2i in 🏥 for #COVID19
Full slideset available in 👇https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu
— Enrique Santas (@SantasEnrique) May 16, 2021
DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ
— American College of Cardiology (@ACCinTouch) May 16, 2021
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.
17 May, 2021 | 08:45h | UTC‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT
Setting the record straight: There is no ‘Covid heart’.
17 May, 2021 | 08:47h | UTCSetting the record straight: There is no ‘Covid heart’ – STAT
Commentary on Twitter
Why the issue of Covid-19 induced cardiac problems was massively overblown and why screening low-risk patients with MRI and other fancy tests is neither necessary nor wise. https://t.co/HkJFOJ6oeM
— Raffaele Rasoini (@RasoiniR) May 14, 2021
#ACC21 – RCT: No significant differences in cardiovascular events or major bleeding between patients receiving 81 mg vs. 325 mg of aspirin daily.
17 May, 2021 | 08:31h | UTCComparative Effectiveness of Aspirin Dosing in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE – TCTMD AND Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness – ADAPTABLE – American College of Cardiology
Video: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
#ACC21 – RCT: Tailored, earlier heart failure rehabilitation program has physical and emotional benefits for older patients.
17 May, 2021 | 08:23h | UTCCommentaries: Tailored, earlier heart failure rehab has physical, emotional benefits for patients – National institutes of Health AND REHAB-HF: Tailored Cardiac Rehab Program Improved Function and Quality of Life in Older HF Patients – American College of Cardiology AND Rehabilitation Therapy in Older Acute Heart Failure Patients – REHAB-HF – American College of Cardiology
Commentaries on Twitter
#REHAB-HF #ACC21 innovative intensive rehab improved physical function
-attention to SDOH environment assessment & involvement of family/care givers
-q2 wk trouble shooting discussion
-corrected balance/mobility first to get pts on treadmill w confidence https://t.co/rOmsc6qdq3 pic.twitter.com/V8TugBipUT— Ritu Thamman MD (@iamritu) May 16, 2021
REHAB-HF trial results found novel #CVRehab program tailored to address specific physical impairments in frail/older patients w/ acute #HeartFailure improved physical function & quality of life; did not significantly reduce hospitalizations. https://t.co/f98IdMvqj4 #ACC21 #cvGeri pic.twitter.com/zY8E1WBNmf
— American College of Cardiology (@ACCinTouch) May 16, 2021
#ACC21 – [Not published yet] RCT: PARADISE-MI: Sacubitril/Valsartan did not outperform ACE inhibitor after myocardial infarction with new onset heart failure.
17 May, 2021 | 08:17h | UTC
#ACC21 – [Not published yet] RCT: Among patients undergoing TAVR, full-dose apixaban is not superior to standard of care (vitamin K antagonist if indication for oral anticoagulation; antiplatelet therapy if no indication).
17 May, 2021 | 08:19h | UTCCommentaries: ATLANTIS: Apixaban Not Superior to Standard Care After TAVR – American College of Cardiology AND ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI – TCTMD
2 recent meta-analysis highlight the benefits of short term (30 days) dual antiplatelet therapy with aspirin + clopidogrel in patients within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke.
17 May, 2021 | 08:16h | UTCMeta-analysis 1: Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials – Stroke
Meta-analysis 2: Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials – Circulation (link to abstract – $ for full-text)
Commentary: Dual vs. Monotherapy Antiplatelet Agents in Secondary Stroke Prevention – American College of Cardiology
Related Guideline: Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ
Unnecessary care? 1 in 3 patients with advanced dementia and atrial fibrillation still given anticoagulants.
17 May, 2021 | 08:13h | UTCOriginal study: Anticoagulant Use for Atrial Fibrillation Among Persons With Advanced Dementia at the End of Life – JAMA Internal Medicine (free for a limited period)
Editorial: Anticoagulation at the End of Life: Time for a Rational Framework (free for a limited period)
Opinion | Reconceptualizing how to support surrogates making medical decisions for critically ill patients.
17 May, 2021 | 08:08h | UTCReconceptualizing How to Support Surrogates Making Medical Decisions for Critically Ill Patients – JAMA (free for a limited period)
Report: Implementing high-quality primary care – “pay for primary care teams to care for people, not physicians to deliver services”.
17 May, 2021 | 08:11h | UTCOriginal report: Implementing High-Quality Primary Care: Rebuilding the Foundation of Health Care – National Academies of Sciences, Engineering, and Medicine
Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications.
14 May, 2021 | 08:43h | UTC
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
14 May, 2021 | 08:46h | UTCHeterologous prime-boost COVID-19 vaccination: initial reactogenicity data – The Lancet
Commentaries: More side effects noted after using 2 different COVID vaccines – CIDRAP AND Covid vaccines: Mixing increases reports of mild side-effects – BBC
Perspective | Vaccines seem to work well against coronavirus variants. It’s also complicated.
14 May, 2021 | 08:41h | UTCVaccines seem to work well against coronavirus variants. It’s also complicated – STAT